Chinese pharmaceutical company manufacturing antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products; the largest listed pharmaceutical company in China.
相关临床试验
425
45 进行中
药物批准
360
批准总数
监管机构
1
监管机构数
成立时间
1997
进行中（未招募）
25
5.9%
已完成
24
5.7%
尚未招募
20
4.7%
招募中
31
7.3%
终止
2
0.5%
Unknown
323
76.0%
- Hengrui Pharma and its subsidiaries received NMPA clinical trial approvals for five oncology drugs, including HRS-6093, a novel oral KRAS G12D inhibitor with no similar approved products globally. - The approved pipeline includes SHR-9839, a dual-pathway blocking humanized antibody, and SHR-1826, a c-Met targeting antibody-drug conjugate with cumulative R&D investments totaling over RMB 400 million. - The company's adalimumab injection, already approved for small cell lung cancer treatment in 2023, received additional clinical trial approval alongside SHR-8068, an anti-CTLA-4 monoclonal antibody. - Total cumulative R&D investment across all five programs amounts to approximately RMB 789.27 million, reflecting significant commitment to oncology drug development.
- GSK5764227 (HS-20093) is an investigational HER2-directed antibody-drug conjugate being developed through collaboration between GSK and Hansoh Pharma for patients with HER2-expressing solid tumors. - The ARTEMIS-001 first-in-human Phase I trial is evaluating safety, tolerability, and preliminary antitumor activity in heavily pretreated patients with advanced or metastatic HER2-positive cancers. - Early clinical data indicate manageable safety profile with predominantly low-grade adverse events and biological activity across multiple HER2-expressing tumor types, including patients previously treated with other HER2-targeted therapies. - The next-generation ADC is engineered to address limitations of first-generation HER2 conjugates through optimized drug-to-antibody ratio, linker stability, and tumor-selective payload release.
- QureBio's Q-1802, a CLDN18.2/PD-L1 bispecific antibody, demonstrated a 70% overall response rate and 11.3-month median progression-free survival in 60 patients with advanced gastric/gastroesophageal junction cancer. - The Phase Ib/II trial showed manageable safety profile with no dose-limiting toxicities observed and only 6.5% permanent discontinuation rate due to adverse events. - Response rates improved to 81.8% in patients with high CLDN18.2 expression and PD-L1 CPS≥5, supporting advancement to Phase III trials. - Chinese regulatory authorities have approved the Phase III trial for Q-1802 at the recommended 10 mg/kg dose in combination with XELOX chemotherapy.
- Hengrui Pharma marked its first-ever exhibition booth at ESMO 2025, presenting 46 oncology research studies across 14 innovative therapeutic programs, including four late-breaking abstracts and nine oral presentations. - The company showcased breakthrough data spanning over 10 cancer types, with notable presentations including a late-breaking abstract on trastuzumab rezetecan ADC for HER2-positive breast cancer and global data from the CARES-009 study. - This milestone represents Hengrui's decade-long participation at ESMO since 2016, with 119 total research achievements presented between 2023-2025, demonstrating China's growing presence in global oncology innovation.
- Hengrui Pharmaceutical received NMPA approval for Ivarmacitinib Sulfate Tablets, a second-generation JAK1 inhibitor, for treating severe alopecia areata in China. - Phase III clinical trials demonstrated a 40% response rate at 24 weeks compared to 9% for placebo, representing a significant therapeutic advancement for patients with this autoimmune condition. - The drug is already approved in China for multiple autoimmune conditions and has secured a $223 million licensing deal with Arcutis for North American and European markets. - Hengrui reported 21.78% year-over-year revenue growth to ¥13.6 billion in 2024, with innovative drug sales surging 33.25%.
- Hengrui Pharma showcased 15 innovative drugs across 72 research outcomes at the 2025 ASCO Annual Meeting, including 4 oral presentations and 5 rapid oral presentations. - The company presented 19 breast cancer studies featuring pyrotinib, dalpiciclib, and other agents, with pyrotinib appearing in 7 studies and dalpiciclib in 6 studies. - Camrelizumab dominated gastrointestinal cancer research with inclusion in 21 of 30 studies, reinforcing China-developed PD-1 inhibitors' global presence. - The presentations reflect Hengrui's portfolio of 23 marketed innovative drugs and pipeline of over 90 candidates in development, marking 15 consecutive years of ASCO participation.
- QureBio completed a Series C1 financing round raising nearly CNY 100 million (approximately USD 14 million) led by Efung Capital to accelerate clinical trials of its novel antibody therapeutics. - The company's lead candidate Q-1802, a Claudin18.2/PD-L1 bispecific antibody for gastric cancer, has completed Phase II enrollment and is preparing for Phase III trials in China. - QureBio has established strategic partnerships with leading pharmaceutical companies including Hengrui Pharma and BioMap, leveraging its proprietary I2T platform and T-cell engager technologies.
